EMMA · Emmaus Life Sciences, Inc. · Executive Compensation
$0.03
+0.01 (+22.99%)
At close · Aug 21
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Because the Company's existing cash balance and anticipated cash flows cannot satisfy its current debt and ongoing obligations, combined with the uncommitted nature of the Company's financing plans, there is substantial doubt about the Company’s ability to continue as a going concern for 12 months from the date that these condensed consolidated financial statements are issued.”View the 10-Q filed Aug 14, 2026
Market Cap
$2.25M
Shares
70.19M
Volume · Aug 21
847.1K
Avg daily vol (3M)
157.21K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Yutaka Niihara | M.D., MPH Chairman of the Board and Chief Executive Officer | $484,203 |
| Yasushi Nagasaki | Chief Financial Officer | $350,000 |
| Willis C. Lee | M.S. Chief Operating Officer | $340,000 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Yutaka Niihara | M.D., M.P.H. Chairman and Chief Executive Officer | $385,000 |
| Yasushi Nagasaki | Chief Financial Officer | $240,000 |
| Willis C. Lee | Chief Operating Officer | $240,000 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Yutaka Niihara | M.D., M.P.H. Chairman and Chief Executive Officer | $385,000 |
| Willis C. Lee | Chief Operating Officer | $240,000 |
| Yasushi Nagasaki | Chief Financial Officer | $235,000 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Henry H. Du | Director | Appointed | 2026-04-17 |
| Jon Kuwahara | director | Resigned | 2026-04-14 |
| Ian Zwicker | director | Resigned | 2025-12-19 |
| Hiroko Huynh | Chief Accounting Officer | Appointed | 2025-07-01 |
| Yasushi Nagasaki | Chief Financial Officer | Resigned | 2025-07-01 |
| Seah Lim, M.D., Ph.D. | director | Resigned | 2024-11-06 |
| Jon Kuwahara | Chair of the two-person Audit Committee of the Board | Appointed | 2024-10-04 |
| Jon Kuwahara | member of the Board of Directors | Appointed | 2024-10-04 |
| George Sekulich | member of the Board of Directors | Resigned | 2024-10-04 |
| Willis Lee | Chief Executive Officer | Appointed | 2024-07-17 |
| Yutaka Niihara | Director | Resigned | 2023-10-04 |
| Willis Lee | Chairman of the Board of Directors | Appointed | 2023-10-04 |
| George Sekulich | Director | Appointed | 2023-10-04 |
| George Sekulich | interim Co-President | Appointed | 2023-08-23 |
| Willis Lee | interim Co-President | Appointed | 2023-08-23 |
| Seah H. Lim, M.D., Ph.D. | director | Appointed | 2022-10-06 |
| Ian Zwicker | director | Appointed | 2022-10-06 |
| Dr. Masaharu Osato | member of the Board of Directors | Resigned | 2022-09-30 |
| Robert Dickey IV | director | Resigned | 2022-08-10 |
Leadership
- Willis Lee CEO, Chairman
- Willis C. Lee COO, Board Member
- George Sekulich CIO, Board Member
- Hiroko Huynh Chief Accounting Officer
- Alfred Lui Board Member
- Henry H. Du Board Member
- Ian Zwicker Board Member
- Jane Pine Wood Board Member
- Jon Kuwahara Board Member
- Lori Teranishi Board Member
- Seah H. Lim, M.D., Ph.D. Board Member
- Wei Peu Derek Zen Board Member